AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 291 min read$MLTX

Reich Kristian sold $22K of MLTX (indirect holdings)

Reich Kristian (Chief Scientific Officer) sold 1,100 indirectly-held shares of MoonLake Immunotherapeutics (MLTX) at $20.00 on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reich Kristian
Published Jul 29, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MLTX
Neutral
high confidence
Mentioned
$MLTX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLTXNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale of 1,100 shares at $20/share on 2026-07-27, reported via a 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and lack of new business information make it low-signal.

03

What to watch

The transaction is indirect and under a pre-arranged plan, so it may not reflect new negative information; also, the dollar amount is relatively small versus typical institutional flows.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-29 after-hours; reflects sale executed 2026-07-27.

Background

The article is an SEC Form 4 insider transaction disclosure for MoonLake Immunotherapeutics (MLTX).

Company-level read

Ticker impact

$MLTXNeutralHigh confidence
Context

MoonLake Immunotherapeutics (MLTX) is the Form 4 issuer, with its Chief Scientific Officer selling 1,100 shares at $20 on 2026-07-27 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any reaction is likely muted.

Evidence & confidence

The disclosure is an open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, and provides no new operational, clinical, or financial datapoint.

Market effects

Sector

Minimal, as the filing does not disclose sector-wide regulatory, trial, or competitive changes.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can coincide with internal risk management or diversification, which some traders may still monitor.

Key entities

  • issuer
    MoonLake Immunotherapeutics

    Company that filed the Form 4 as the insider transaction issuer.

  • insider
    Reich Kristian

    Chief Scientific Officer who sold shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MLTX insider trading history →

Related articles

SEP 8
$MUMed

Dow, S&P 500, Nasdaq Futures Slip As Trump Calls Iran’s Peace Proposal ‘Totally Unacceptable’ — MU, SNDK, MRAM, MLTX Stocks In Focus

U.S. stock futures fell Sunday night after President Trump rejected Iran's peace proposal, raising concerns about global energy supplies. Dow, S&P 500, and Nasdaq futures declined, while oil prices rose. Micron (MU) and Sandisk (SNDK) shares surged over 5% due to high demand for memory chips. Everspin (MRAM) and MoonLake (MLTX) also saw significant gains.

stocktwits.com2 min
SEP 5
$MLTXMedAI 8/10

MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts

MoonLake Immunotherapeutics (MLTX) shares rose 2.5% as investors anticipate late-stage trial results for its lead drug, sonelokimab, focusing on hidradenitis suppurativa. Full 52-week data is expected in Q2, with FDA submission planned for September 2026. Analysts' average price target is $27.62, implying 46% upside. MLTX stock has gained 63% this year, with retail sentiment turning bullish.

stocktwits.com2 min
AUG 11
$MLTXMed

MoonLake’s nanobody boosts PsA indication hopes after Phase III success

MoonLake Immunotherapeutics said its Phase III IZAR-1 trial of sonelokimab in biologic-naive adults with active psoriatic arthritis met the primary endpoint at week 16. In the 60 mg arm, 42.1% achieved ACR50. Secondary results included ACR20 66.5%, MDA 41.2%, PASI90 61%. Patients will be followed 52 weeks, with durability data expected in H1 2027. MoonLake is also running IZAR-2 versus AbbVie’s Skyrizi.

yahoo.com6 min
AUG 10
$MLTXMedAI 8/10

MoonLake's Sonelokimab Meets All Endpoints In Phase 3 PsA Trial

MoonLake Immunotherapeutics (MLTX) reported topline Phase 3 IZAR-1 results for Sonelokimab in biologic-naive adults with active psoriatic arthritis. The trial met the Week 16 primary endpoint, with 42.1% on 60 mg achieving ACR50. Secondary results included 66.5% ACR20, 41.2% MDA, and 61% PASI90. Safety showed no new signals. Full readout is expected in H1 2026.

rttnews.com3 min
AUG 10
$MLTXMedAI 8/10

Why is MoonLake Immunotherapeutics stock plunging today?

MoonLake Immunotherapeutics (MLTX) shares fell 21.7% pre-open to $14.30 after Phase 3 IZAR-1 topline results for sonelokimab in biologic-naive psoriatic arthritis met the primary endpoint. The company reported 42.1% ACR50 at Week 16, plus 66.5% ACR20 and 61% PASI90. Investors reacted negatively due to a BLA submission for hidradenitis suppurativa and future commercialization, with no current revenue and recent dilutive equity raises.

investing.com4 min
AUG 10
$MLTXMedAI 8/10

MoonLake reports positive Phase 3 PsA data and $537 million cash

MoonLake Immunotherapeutics (MLTX) reported positive topline Week 16 Phase 3 IZAR-1 results for sonelokimab 60 mg in biologic-naive adults with psoriatic arthritis, saying all clinical endpoints were met. It reported 42.1% ACR50 at Week 16 and Q2 2026 net loss of $61.8M, ending with $537.0M cash. R&D was $50.2M. It expects cash runway to mid-2028.

quiverquant.com4 min